Framework agreement for the purchase of Zolgensma® (onasemnogene abeparvovec)

This framework agreement aims to ensure the supply of the pharmaceutical product Zolgensma® (onasemnogene abeparvovec) to the hospital pharmacies of Amgros' stakeholders. Amgros, a procurement company for the Danish hospital sector, is facilitating this agreement to provide access to this critical medication. The agreement specifically covers the procurement of Zolgensma®, a gene therapy used for treating spinal muscular atrophy (SMA), a rare and severe genetic disease. The Central Hospital Pharmacy of the Capital Region of Denmark will also undertake purchases for resale to Greenland and the Faroe Islands, extending the reach of this essential treatment to these autonomous territories. The objective is to establish a streamlined and efficient procurement process, ensuring timely availability of Zolgensma® for eligible patients across the specified regions. This initiative underscores a commitment to providing advanced therapeutic options and equitable access to specialized medicines within the Danish healthcare system and its associated territories. The framework agreement is expected to define terms, conditions, and pricing for the supply of Zolgensma®, facilitating predictable and cost-effective acquisition for the participating hospital pharmacies.

This is a supplies contract in the health and medical services sector, with a focus on Hospitals and Pharmaceuticals. Located in Denmark, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.